INTRODUCTION
Metal-based antitumour drugs constitute in our days a broad research area of increasing interest/1-4/.
Concretely, cisplatin, cis-[Pt(NH3)2C12], carboplatin [cis-diammine-I, -cyclobutanedicarboxylatoplatinum(II)] and oxaliplatin [trans-(R,R)-l,2-diamminecyclohexaneoxalatoplatinum (II)], are currently being used clinically /5-10/. However, the problem of both acquired and inherent resistance of tumour cells presents a main limitation to the more widespread clinical use of platinum complexes/3,7,9/. In the hope of overcoming these limitations, other platinum-based antitumour drugs have been synthesized and tested for antitumour activity/11-15/. Furthermore, new anticancer drugs containing transition metal ions other than platinum /16/have been also assayed. Possible advantages may involve different coordination geometries, several metal-ion oxidation states and biological targets other than DNA.
In the design of these new drugs, ruthenium complexes have raised great interest/17-24/. As an example, the antitumour activity of the highly water soluble complex H[Ru(H2L)CI]-4H20 (H4L: 1,2- propylenediammine-N,N,N',N'-tetraacetic acid, pdta) has been evaluated in vivo and in vitro/23,25/. This complex rapidly binds to serum proteins producing stable adducts in which the core Ru(lII)(pdta) is probably bound to histidines on the protein surface/26-28/. On the other hand, the complex damages nuclear DNA, inhibits DNA recognition and stimulates NADPH oxidase and a respiratory burst in phagocytic neutrophils and elicits phosphorylation of tyrosine residues/25,29/.
Another interesting ligand is the potential hexadentate sequestering agent trans-l,2-cyclohexanediamminetetraacetic acid (cdta), in which the ethylenediammine group of edta has been replaced by the heterocyclic moiety trans-l,2-cyclohexanediammine. The ligand cdta is widely used nowadays in varied applications, i.e., as detoxifier of heavy metals that contaminate patients/30/, for use in endodontics /31/, for extraction of pectin polymers /32/ and for separation and quantitation by several techniques of inorganic ions and anionic metal complexes/33/. Although the metal complexes formed by cdta are known from time ago/34/, recent literature has shown new synthesis procedures and important properties of new isolated complexes. Concretely, those formed by cdta with Cu (ll) and Ni (ll) have been studied by X-ray photoelectron spectroscopy and X-ray crystal diffraction studies /35,36/ and 
Biological in vitro and in vivo assays
Complex was dissolved in a mixed 1:1 DMSO:H20 solution and used as concentrated stock solution from which diluted solutions (I/10 dilt/tion factor) were prepared and added to growing culture medium of each one of the cellular types included in the study. The in vitro assays were done against three different human cancer cell cultures: malignant melanoma (ADLD), uterine neck carcinoma (HeLa) and colon adenocarcinoma . For determination of plating efficiency and colorimetric reading, we prepared plates of 24 and 96 wells, respectively, that were then inoculated with 5,000 to 30,000 cells/well. After 24 h from the inoculation, different concentrations of the testing product were added to the cancer cells. After 48 h of the named addition, the cells were washed and then fixed. Finally, the coloring and reading of the plates were carried out. In all cases we determined the number of cells at the beginning (Tot), just before the addition of the testing products (To) and 48 h later (T controls and T tests), according to Scheme 1.
The antitumour activity of was tested in vivo against Ehrlich ascitic tumour (EAT), the intraperitoneally-implanted P388 lymphocytic leukemia and the subrenal capsule (transplanted human mammary carcinoma) MX-I xenograft. The experiments were performed according to the NIH protocols at ONI Centre, Madrid, Spain. CD2F female mice with weights within a 3 g value range and a minimum weight of 18 g were used for all experiments except for MX-1 carcinoma, where athymic swiss mice were used (4 g value range and weight of 17 g). The test groups was formed by 6 animals and control group by 12. Synthesis of the complex [RuV(HL)CI].2HO [1] Solid cdta (228 mg, 1.0 mmol) was added to a clear solution of RuCI3 (0.230 RESULTS AND DISCUSSION X-ray structure (2) o (I l -Ru (I) -cl. (2) O (2.) -Ru (I) -CI {2) I.i (I) -Ru (I) -el (2) (1) 173. 48 (8) 80.72 (9) 94.89 (8) 95.57
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The potentiometric titration of an aqueous solution of the complex (Fig. 4a) shows a sharp increase of pH for the consumption of 2 g-equiv, of alkali with an inflection point registered at pH 6.9 . Furthermore, a change in the electrical conductivity of the solution is also observed at A equal to 168 S cm (Figure 4b ), 
Infrared spectroscopy
The FT-infrared spectrum of compound 1 (not shown) presents a broad, split signal with main peaks at 2940 cm and 2902 cm 1 corresponding to the symmetric stretching vibrations (vs) of the methylene groups (C-H bonds) contained in the heterocyclic ligand and of the same groups next to coordinated and free carboxylic groups. The O-H stretching vibrations of the free COOH groups are responsible for the broad absorptions registered between 3350 cm and 2600 cm. The complex shows strong characteristic bands registered at 1735 cm (vas, C=O bond of free carboxylic groups) and 1610 cm (Vas COO-coordinated carboxylate groups) whereas the Vs of coordinated carboxylate groups appeared at 1400 cm-. The difference of 210 cm between v, and vs of coordinated carboxylate groups indicates the predominantly ionic character of complex 1. -1 Water normally gives broad absorption at about 3400 cm Complex shows indeed a broad and intense -I band around 3350 cm that might be attributed to the hydration water molecules most likely bonded to anionic coordinated moieties through hydrogen bonds/55/. Table 3 presents the main bands observed in the infrared spectrum of complex I.
Cyclic voltammetry
The cyclic voltammogram (CV) of just prepared 4.0 mM aqueous solutions (pH 2.0) of complex (NaCIO, 0.15 M) is presented in Fig. 5 . At electric potentials between +0.5 V and -0.5 V, the CV show a cathodic wave (A) immediately followed by the anodic wave (A'), both clearly constituting a coupled pair, AA'. If the potential varies between +1.5 V and -1.5 V, an intense cathodic peak is observed at about-0.8 V, while an anodic prominent peak appears at about 1.0 V. These features could be attributed to redox processes affecting the ligands/58/. Table 4 presents the cyclovoltammetric parameters corresponding to the coupled pair AA', characteristic (40.8 luM) .
To determine if this cytotoxic behaviour holds true for other human tumours, the inhibition assay was repeated against the human malign melanoma ADLD (Fig. 7 ) whose proliferation rate (control curve) is higher than that observed for HeLa cells. A substantial increase of the antiproliferative properties was detected against this melanoma at the same doses assayed against HeLa carcinoma. At a dose of 25. 4 IuM, (curve a) the inhibition of ADLD cells is not only more important that in the previous assays but increases with increasing time (inhibition of about 33% after 72 h; 42.4% on the fourth day, and 46.4% on the last day). If the dose is increased (40.8 M) the same general pattern is observed (increasing cytotoxicity at increasing time) and the complex shows important antiproliferative response next to 70% during the last two days of treatment (curve b). Fig. 8 shows the antiproliferative behaviour of complex against the colon adenocarcinoma cell line HT-29. As can be seen, the cell growth observed in this culture (control curve) is slightly slower than HeLa cell culture while the cytotoxic study indicates that ruthenium complex exhibits discrete cell inhibition activity at both doses assayed. The analysis of the antiproliferative curve at the low dose (25.4 IuM, curve a) shows that ruthenium complex behaves in a similar way to that analyzed for HeLa cells (the inhibition remains constant after three days of treatment), but the antiproliferative activity decreased to about 20%, if compared to that observed at this dose for HeLa cells (27%). When the dose is increased (40.8 IuM, curve b), the observed cell inhibition after 72 h of treatment is enhanced to 25%. Interestingly, this inhibition also remains constant during the treatment. 
()./'the Complex
The in vivo antitumour activity of complex against EAT and P388 tumours was evaluated at several treatment doses in the range 20--240 mg/kg body weight. The therapeutic activity of the complex was obtained from the T/C percentage which is described as T/C% (100) x mean life span of treated mice/mean life span of untreated mice; turnout free survivors were excluded. The minimum value of T/C for moderate activity is 120 (EAT and P388 tumours); if T/C > 125 the complex is considered a candidate for further antitumour assays. T/C values required for activity in MX-1 xenograft tumour must be lower than 20 (T/C <20).
For EAT, a T/C (%) of 350 was obtained (25 mg/kg) and the complete remission of the turnout observed at a dose of 50 mg/kg. The toxic .dose (LDs0) was equal to 100 mg/kg. In the case of the lymphocytic leukemia P388, a T/C(%) value of 140 was obtained (60-120 mg/kg) while in MX-I xenograft carcinoma, this parameter was equal to 16 at a dose of 240 mg/kg.
These results evidence a notable and specific antiproliferative effect of complex [Ru(HzL)CI2]'2H20 against the human tumour cell lines ADLD and HeLa, with selective and important cytotoxic properties in both cases. The in vivo antitumour activity is also remarkable in the studied turnouts. A further investigation of the antineoplastic activity of this new potential ruthenium drug against other types of turnout is advisable.
